Resolute Science is a preclinical-stage biotechnology company developing a novel class of pan-cancer therapeutics for the treatment of aggressive and hard-to-treat solid tumors. By leveraging its proprietary MAC-TAC drug-delivery platform, Resolute is advancing a broad pipeline of first-in-class targeted cytotoxic payloads, radiopharmaceuticals, and imaging agents. Its lead asset, RS-5, is undergoing IND-enabling studies, with two additional preclinical programs underway. Resolute Science's mission is to help people with cancer recover and return to their normal lives.